To Evaluate the Safety and Efficacy of Intracranial Stent Assisted Endovascular Treatment of Intracranial Aneurysms

Inclusion Criteria:

• Aged from 18 to 80 years, male or female;

• Patients diagnosed as wide-neck intracranial aneurysms by brain CTA/MRA/DSA (neckwidth≥4mm or bodyor a dome-to-neck ratio<2);

• Parent vessel with a diameter of ≥2.5mm and ≤4.5mm;

• Patients target aneurysm is planned to be embolized using intracranial stentassisted with coiling;

• The mRS Score of the patients was 0-2;

• Patients understand the purpose of the study, accept the follow-up period, and agreeto comply with all requirements, agree to participate in the clinical trial andvoluntarily sign the informed consent.

Exclusion Criteria:

• Patients who have contraindications to antiplatelet and/or anticoagulant therapy ordo not start antiplatelet therapy in time before treatment.

• Patients with anatomical structure is not suitable for endovascular treatment due tosevere vascular tortuosity or stenosis shown by angiography.

• Known to be allergic to Nitinol platinum alloy and angiographic agents.

• Conditions that in the opinion of the investigators would prevent patients fromcompleting the study, such as the expected survival period of active tumor less than 1-year, high-risk group of cerebral thrombosis, heart failure and atrialfibrillation.

• Patients combined moyamoya disease, intracranial tumor, intracranial arteriovenousmalformation, intracranial arteriovenous fistula and intracranial hematoma.

• The target aneurysm has previously received intravascular embolization or stentimplantation treatment;

• Multiple aneurysms or complex aneurysms;

• Patients with acute ruptured aneurysm;

• Serious infection is not controlled and is not suitable for operation;

• Patients who underwent major surgery or interventional therapy (such as brain,cardiac, chest, abdominal or peripheral vascular) within 30 days before surgery;

• Obvious abnormal coagulation function or bleeding tendency;

• Combined with severe renal insufficiency, creatinine greater than or equal to 200umol/L; Patients with severe liver diseases (such as acute and chronic hepatitis,cirrhosis), or ALT more than 3 times the upper normal limit;

• Pregnancy, lactation, or women of childbearing age who plan to be pregnant duringthe study period;

• Participation in any other clinical trial within 30 days prior to signing informedconsent;

• Other conditions considered by the investigator to be inappropriate for enrollment.